Corline Biomedical AB (“Corline”) is publishing hereby the interim report for the period January to march 2017. Below is a brief summary of the report. The full interim report is available on the Corlines website (
www.corline.see
) as well as attachment.
Significant events during the first quarter of 2017
-
In the beginning of February 2017 communicated to both Corline which the EUROPEAN commission has signed anslagsavtalet of approximately MSEK 23.1, why the payment of the first instalment can be made.
-
On February 7, 2017 announces Corline to NPITG, a subclass of Scandiatransplant, wish to review the pre-clinical data before Cytoparin(TM)-the study is started. Start is postponed, consequently compared with previous communication.
-
On 16 February 2017 announces Corline, the Company held a meeting with representatives of the NPITG and shortly thereafter communicated to NPITG recommended that the start of the Company’s study with Cytoparin(TM) is postponed pending further clinical data.
-
The 31 march 2017, announces Corline to Renaparin® demonstrated a high margin of safety in a toxikologistudie according to Good Laboratory Practice (GLP).
Significant events after the first quarter
-
On april 3, 2017 announces Corline Henrik Krook proposed for election at the company’s board of directors. Krook has extensive knowledge in the transplantation sector and over 15 years of experience from various positions at pharmaceutical companies such as Roche, Novartis, Medivir and Alexion.
-
The annual general meeting to be held on 4 may 2017. On the same day notifies the Corline to the company, the substance received särläkemedelsstatus in the united states for the indication organ transplantation. Corline has subsequently särläkemedelsstatus for this indication in both its target markets, the united states and Europe.
Economic overview over the first quarter of 2017
-
Net sales in the first quarter amounted to 217 THOUSAND (216).
-
The result after financial items for the first quarter amounted to sek -3 085 KSEK (-1 835).
-
Earnings per share for the first quarter amounted to approximately -0,24 $ (-0,19).
-
Cash and cash equivalents amounted as per 31 march 2017 to 16 MILLION.
For complete interim report, see
www.corline.com
Certified Adviser
Subsequently, the Brokerage is Corlines Certified Adviser.
For more information on the Corline, please contact
Henrik Nittmar, CEO
Telephone: 018-71 30 90
E-mail: henrik.nittmar@corline.se
This information is such information that Corline Biomedical AB is obliged to publish under the EU marknadsmissbruksförordning and the law on the securities market. The information was submitted, by the above contact person in the government, for publication on 18 may 2017.
Corline Biomedical AB
working with the endogenous substance heparin and has developed a portfolio of candidate drugs for use in conjunction with organ – and cell transplantation. The company is planning clinical studies in type 1 diabetes and kidney transplant, for which the Corline also has received särläkemedelsstatus (“Orphan Drug”). Within the framework of a wholly owned subsidiary of Corline Pharma AB evaluated the in vivo administration of Corlines heparinsubstans and then past ytbelägger the company medical devices and has handled over 100 000 hjärtstentar implanted in patients. The new drug candidates are based on the same basic technology as medical devices.
Corline Biomedical AB interim report January – march 2017
